Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 11.4 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), a shelf registration filed Jun 5, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$15.3MCash on Hand
11.4mo Cash Runway
Follow GNPX by emailGet an email when GNPX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GNPX, unsubscribe in one click. Privacy
📣 What GNPX Says Is Next
the end of 2026 · “Genprex anticipates completing these validation studies by approximately the end of 2026, with subsequent integration into its NSCLC clinical program shortly thereafter, dependent on the results of the validation studies.”
Company press release, Aug 3, 2026 · SEC filing
by the end of 2026 · “We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study by the end of 2026 and expect the interim analysis in the first half of 2027.”
Company press release, Jul 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Clinical trial Genprex reported translational data from 11 lung cancer patients treated with REQORSA, showing a biphasic whole-blood gene response: an early innate immune response at 5 hours, then a shift toward cellular maintenance, repair and quality control at 24 hours. Results were presented at GSA 2026. Form 8-K · SEC filing
Nov 4, 2026 ·
Genprex announced preclinical and supporting clinical research identifying low TROP2 expression as a potential predictive biomarker of resistance to Reqorsa in non-small cell lung cancer. The findings will be presented as a poster at the EORTC-NCI-AACR Symposium on November 18, 2026 in Barcelona. Form 8-K · SEC filing
Oct 28, 2026 ·
Genprex said research from its Meharry Medical College collaboration on TUSC2, the gene in its lead candidate REQORSA, will be presented as a poster at the GSA 2026 Annual Scientific Meeting on November 4, 2026. Form 8-K · SEC filing
Oct 21, 2026 ·
Genprex issued a press release on a peer-reviewed mouse study from Meharry Medical College linking the TUSC2 gene, the target of its investigational REQORSA cancer gene therapy, to healthy brain aging. The study found sex-specific effects and TUSC2 expression declining with age in 11 of 13 human brain regions. Form 8-K · SEC filing
Aug 18, 2026 ·
Deal Entered a development and manufacturing agreement with a U.S. CDMO to scale up production of its AAV-based diabetes gene therapy, with cGMP manufacturing to supply IND-enabling studies and future clinical trials. No deal payment amounts were disclosed. Form 8-K · SEC filing
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 1/2 · Recruiting · Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients Registry primary completion date, not a results date
Mar 2028 · Phase 1/2 · Recruiting · Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not GNPX's own candidates): Atezolizumab, Dexamethasone, Diphenhydramine Hydrochloride, Erlotinib Hydrochloride, Cisplatin, Docetaxel Anhydrous, Pembrolizumab, Ramucirumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GNPX holds $15.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $4M/quarter from operations,
an estimated runway of 11.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 11 months +30
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Jun 2026) +10
Going-concern doubt in the latest 10-Q +15As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Jun 5, 2026 · Shelf registration, up to $250M · S-3
Share count 1,334,753 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GNPX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GNPX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.